A gene mutation in RNA‑binding protein 10 is associated with lung adenocarcinoma progression and poor prognosis

Yin,Lin‑Lin; Wen,Xin‑Mian; Li,Ming; Xu,Yan‑Mei; Zhao,Xiao‑Feng; Li,Jing; Wang,Xiu‑Wen

doi:10.3892/ol.2018.9496

A gene mutation in RNA‑binding protein 10 is associated with lung adenocarcinoma progression and poor prognosis

Authors:
- Lin‑Lin Yin
- Xin‑Mian Wen
- Ming Li
- Yan‑Mei Xu
- Xiao‑Feng Zhao
- Jing Li
- Xiu‑Wen Wang
View Affiliations

Affiliations: Department of Oncology, Qilu Hospital, Shandong University, Jinan, Shandong 250000, P.R. China, Department of Clinical Laboratory, The Fourth Hospital of Jinan, Jinan, Shandong 250031, P.R. China, Department of Chest Surgery, Shandong Chest Hospital, Jinan, Shandong 250013, P.R. China, Department of Pathology, Shandong Shanxian Central Hospital, Heze, Shandong 274300, P.R. China, The Joint Laboratory for Translational Medical Research, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Hematology and Oncology, The Fourth Hospital of Jinan, Jinan, Shandong 250031, P.R. China
Published online on: September 24, 2018 https://doi.org/10.3892/ol.2018.9496
Pages: 6283-6292
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RBM10 regulates the expression of various genes, which are often mutated in male lung adenocarcinoma. The present study confirmed the association of the RBM10 mutation at exon 10 with the clinicopathological data and prognosis of lung adenocarcinoma. The effect of mutant RBM10 on regulating lung cancer cell growth and invasion was investigated in vitro. Tissue specimens from 50 patients with lung adenocarcinoma were subjected to Sanger sequencing for RBM10 exon 10 mutations. Lung adenocarcinoma cells were transfected with pcDNA3.1 carrying wild type RBM10 cDNA or exon mutation cDNA for cell viability, apoptosis and invasion assays. RBM10 exon 10 mutations were identified in 11 out of 50 patients, with a high frequency in male patients [c.763 C>T, p.Arg241Cys for 33.3% (10/30)] and were significantly associated with the American Joint Committee on Cancer stage (P=0.005), lymph node metastasis (P=0.019) and shorter 5‑year survival rate compared with the wild type RBM10 (36.4% vs. 46.5%; P=0.019). Multivariate analysis revealed that RBM10 exon 10 mutation was an independent prognostic factor (HR=3.787; P=0.033). RBM10 exon 10 mutation at c.763 C>T significantly promoted tumor cell proliferation and invasion capacity, whereas wild type RBM10 inhibited tumor cell invasion in vitro. In conclusion, RBM 10 mutation at exon 10 (c.763 C>T) occurs frequently and is an independent prognostic predictor in lung adenocarcinoma.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cooper WA, Lam DC, O'Toole SA and Minna JD: Molecular biology of lung cancer. J Thorac Dis. 5 Suppl 5:S479–S490. 2013.PubMed/NCBI
4	Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JE and Frei E: Chapter 78: Cancer of the Lung. People's Medical Publishing House; 2010
5	Glisovic T, Bachorik JL, Yong J and Dreyfuss G: RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 582:1977–1986. 2008. View Article : Google Scholar : PubMed/NCBI
6	Mueller CF, Berger A, Zimmer S, Tiyerili V and Nickenig G: The heterogenous nuclear riboprotein S1-1 regulates AT1 receptor gene expression via transcriptional and posttranscriptional mechanisms. Arch Biochem Biophys. 488:76–82. 2009. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Gogol-Döring A, Hu H, Fröhler S, Ma Y, Jens M, Maaskola J, Murakawa Y, Quedenau C, Landthaler M, et al: Integrative analysis revealed the molecular mechanism underlying RBM10-mediated splicing regulation. EMBO Mol Med. 5:1431–1442. 2013. View Article : Google Scholar : PubMed/NCBI
8	Pan Q, Shai O, Lee LJ, Frey BJ and Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 40:1413–1415. 2008. View Article : Google Scholar : PubMed/NCBI
9	David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
10	Sutherland LC, Thibault P, Durand M, Lapointe E, Knee JM, Beauvais A, Kalatskaya I, Hunt SC, Loiselle JJ, Roy JG, et al: Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA. BMC Mol Biol. 18:192017. View Article : Google Scholar : PubMed/NCBI
11	Ji Y, Xie S, Jiang L, Liu L, Li L, Luo L, Chen Y, Zhang J, Yu L, Zhang Y, et al: Increased cell apoptosis in human lung adenocarcinoma and in vivo tumor growth inhibition by RBM10, a tumor suppressor gene. Oncol Lett. 14:4663–4669. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hernández J, Bechara E, Schlesinger D, Delgado J, Serrano L and Valcárcel J: Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol. 13:466–472. 2016. View Article : Google Scholar : PubMed/NCBI
13	Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et al: Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 6:67442015. View Article : Google Scholar : PubMed/NCBI
14	Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
15	Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ganti AK, Huang CH, Klein MA, Keefe S and Kelley MJ: Lung cancer management in 2010. Oncology (Williston Park). 25:64–73. 2011.PubMed/NCBI
17	Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G, Viale G, et al: Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA. 106:22293–22298. 2009. View Article : Google Scholar : PubMed/NCBI
18	Johnston JJ, Teer JK, Cherukuri PF, Hansen NF, Loftus SK; NIH Intramural Sequencing Center (NISC), ; Chong K, Mullikin JC and Biesecker LG: Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate. Am J Hum Genet. 86:743–748. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhao J, Sun Y, Huang Y, Song F, Huang Z, Bao Y, Zuo J, Saffen D, Shao Z, Liu W and Wang Y: Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Sci Rep. 7:404882017. View Article : Google Scholar : PubMed/NCBI
20	Kaida D, Schneider-Poetsch T and Yoshida M: Splicing in oncogenesis and tumor suppression. Cancer Sci. 103:1611–1616. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
22	Israels LG and Israels ED: Apoptosis. Oncologist. 4:332–339. 1999.PubMed/NCBI
23	Inoue A, Yamamoto N, Kimura M, Nishio K, Yamane H and Nakajima K: RBM10 regulates alternative splicing. FEBS Lett. 588:942–947. 2014. View Article : Google Scholar : PubMed/NCBI
24	Ma K, Fan Y, Dong X, Dong D, Guo Y, Wei X, Ning J, Geng Q, Wang C, Hu Y, et al: MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer. Oncotarget. 8:38825–38840. 2017.PubMed/NCBI